US2023331729A1PendingUtilityA1

4-imidazopyridazin-1-yl-benzamides as btk inhibitors

80
Assignee: MERCK SHARP & DOHMEPriority: Jul 19, 2011Filed: Nov 10, 2022Published: Oct 19, 2023
Est. expiryJul 19, 2031(~5 yrs left)· nominal 20-yr term from priority
Inventors:Tjeerd BarfChristiaan Gerardus Johannes Maria JansAdrianus Petrus Antonius De ManArthur A. OubrieHans C.A. RaaijmakersJohannes Bernardus Maria RewinkelJan Gerard SterrenburgJacobus C.H.M. Wijkmans
C07D 487/04C07D 519/00A61K 31/4985A61K 31/501A61K 31/506A61K 31/55A61K 31/5377Y02A50/30A61P 19/08A61P 29/00A61P 31/00A61P 35/00A61P 37/00A61P 1/00A61P 1/02A61P 1/04A61P 1/16A61P 1/18A61P 11/00A61P 11/06A61P 13/02A61P 13/12A61P 17/00A61P 17/06A61P 19/00A61P 19/02A61P 21/04A61P 25/00A61P 27/02A61P 27/06A61P 27/16A61P 31/04A61P 31/12A61P 35/02A61P 37/02A61P 37/06A61P 43/00A61P 5/14A61P 7/00A61P 7/06A61P 3/10
80
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

Claims

exact text as granted — not AI-modified
1 . A method of treating acute lymphocytic leukemia (ALL) in a human subject, the method comprising administering to the human subject a compound that is
 (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide, having the structure:   
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The method of  claim 1 , wherein the compound is present in a pharmaceutical composition. 
     
     
         3 . The method of  claim 2 , wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable auxiliaries. 
     
     
         4 . The method of  claim 2 , wherein the pharmaceutical composition is administered to the human subject by oral administration. 
     
     
         5 . The method of  claim 3 , wherein the pharmaceutical composition is administered to the human subject by oral administration. 
     
     
         6 . The method of  claim 4 , wherein the pharmaceutical composition is a tablet. 
     
     
         7 . The method of  claim 5 , wherein the pharmaceutical composition is a tablet. 
     
     
         8 . The method of  claim 4 , wherein the pharmaceutical composition is a capsule. 
     
     
         9 . The method of  claim 5 , wherein the pharmaceutical composition is a capsule. 
     
     
         10 . The method of  claim 4 , wherein the pharmaceutical composition is a suspension. 
     
     
         11 . The method of  claim 5 , wherein the pharmaceutical composition is a suspension. 
     
     
         12 . The method of  claim 1 , wherein the compound is administered to the human subject in an amount of 0.0001-25 mg per kg body weight. 
     
     
         13 . The method of  claim 1 , wherein (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide is administered to the human subject. 
     
     
         14 . The method of  claim 1 , wherein a pharmaceutically acceptable salt of (S)-4-(8-amino-3-(1-but-2-ynoylpyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide is administered to the human subject.

Join the waitlist — get patent alerts

Track US2023331729A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.